Catalyst Pharma CSO equity canceled in Angelini deal
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Catalyst Pharmaceuticals Chief Strategy Officer Preethi Sundaram reported dispositions tied to the company’s acquisition by Angelini Pharma S.p.A. On July 15, 2026 she disposed of 54,804 shares of common stock at $31.50 per share, and all reported RSUs and stock options were canceled and converted into cash rights, leaving her with no reported common or derivative holdings.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 225,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 67,500 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 68,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 143,193 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 137,553 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 106,873 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 6,855 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 11,206 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 32,257 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 54,804 | $31.50 | $1.73M |
Footnotes (6)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option was fully vested.
- F6. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Key Terms
Restricted Stock Units financial
stock option financial
cash payment financial
Merger financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Catalyst Pharmaceuticals (CPRX) report for July 15, 2026?
What happened to Preethi Sundaram's RSUs in Catalyst Pharmaceuticals (CPRX) after the Angelini merger?
How were Catalyst Pharmaceuticals (CPRX) stock options treated in the Angelini Pharma acquisition?
Does Preethi Sundaram still hold Catalyst Pharmaceuticals (CPRX) equity after the merger?
AI-generated analysis. How Rhea-AI works. Not financial advice.